ImmunoCellular Therapeutics Ltd news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

IMUC 0.119 -0.001 (-0.58%)
price chart
Company Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Announces ...
Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “We are pleased with the progress we made in the first half of this year, and believe that 2016 will be a year of accomplishment for our company.
ImmunoCellular Therapeutics Ltd. (IMUC) Announces Quarterly Earnings Results ...  The Cerbat Gem
Healthcare Worth Watching Stocks: ImmunoCellular Therapeutics Ltd (NYSEMKT ...  Post Registrar
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) Earns Consensus Hold Rating
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) up 1.4% for the past 5 days, is under coverage of 0 analysts who collectively assign a hold rating on stock.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) Reports Net Loss For 2Q2016  Journal Transcript
ImmunoCellular Therapeutics Ltd (IMUC) Given New $2.00 Price Target at Maxim ...  BBNS
ImmunoCellular Therapeutics Ltd. (IMUC) Receives Buy Rating from Maxim Group
ImmunoCellular Therapeutics Ltd. logo Maxim Group reaffirmed their buy rating on shares of ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) in a research report report published on Tuesday. Maxim Group currently has a $2.00 target price on the stock, ...
ImmunoCellular Therapeutics Ltd. (IMUC) Upgraded to "Buy" at Zacks ...  BBNS
Notable Analyst Coverage: Infinera Corp. (NASDAQ:INFN), ImmunoCellular ...  Review Fortune
Analyst Outlook on Price Target: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) plunged -0.58% during previous trade, a total of 3.28M shares exchanged hands compared with its average trading volume of 2.33M shares whereas its relative volume is 2.66.
Company Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Reports ...
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly diagnosed glioblastoma and the phase 1 trial of ICT-121 for recurrent ...
Analysts: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) stock is worth $2.5
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) down -2.94% for the past 5 days, is under coverage of 2 analysts who collectively assign a hold rating on stock.
Important Analyst Opinions about Stock's Earnings: ImmunoCellular ...  Is stories
Noteworthy Analysts Suggestions: ImmunoCellular Therapeutics, Ltd. (NYSEMKT ...  Street Updates
Company Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Announces ...
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to purchase up to 35,250,000 shares of its common stock at a public offering price of ...
Trading Review: Looking at Unusual Volume for ImmunoCellular Therapeutics ...  Engelwood Daily
ImmunoCellular Therapeutics, Limited (NYSEMKT:IMUC) Earns Consensus Hold Rating
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) down -30.52% for the past 5 days, is under coverage of 2 analysts who collectively assign a hold rating on stock.
Two Biotechnology Names Are Hot: Sequenom Inc. (SQNM), ImmunoCellular ...  Zergwatch
Trader's Roundup: ImmunoCellular Therapeutics, Ltd. (AMEX:IMUC)  Post Registrar
Comprehensive Analysis of: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC)
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) reported its last earnings on Aug 04 AMC (BMO = before market open, AMC= after market close).
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) Stock Declines, Analysts ...  Review Fortune
Active Biotech Stock News: ImmunoCellular Therapeutics, Ltd. (IMUC), Ariad ...  Zergwatch
Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Treats First ...
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly diagnosed glioblastoma.